Home > Urology > EAU 2020 > Prostate Cancer & Imaging > Large patient-driven survey reveals QoL issues after prostate cancer treatment

Large patient-driven survey reveals QoL issues after prostate cancer treatment

Presented By
Mr André Deschamps , Europa Uomo, Belgium
Conference
EAU 2020
Trial
EUPROMS
Findings from the EUPROMS study were reported by Mr André Deschamps (Chairman of Europa Uomo, Belgium) [1]. This study represents the first patient-driven quality-of-life (QoL) data collection and revealed specific long-term complaints correlating with a given treatment. Europa Uomo is an umbrella organisation of European prostate cancer patient groups, which practices evidence-based patient advocacy and is active in EAU policy making regarding patient representation. When evidence of patient experience is lacking, organisations like Europa Uomo fill a critical gap in generating independent patient-reported outcomes. In this case, the EUPROMS patient-driven QoL study included data from 2,943 men treated for prostate cancer from 24 countries (mean age 70 years at survey, mean age 64 years at diagnosis). Participants were asked to complete a 20-minute online survey to assay QoL of patients with or who had been treated for prostate can...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on